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Abstract: Treatment of severe burn wounds presents a daunting medical challenge, and novel
approaches promoting healing and reducing scarring are highly desirable. The application of
mesenchymal stem/stromal cells (MSCs) has been suggested as a novel treatment. In this paper,
we present systematic reviews of pre-clinical and clinical studies of MSC therapy for second-
or third-degree thermal burn wounds. Following the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines, the PubMed and Embase databases were searched,
and interventional studies of MSC therapy using rodent models (21 studies) or human burn patients
(three studies) were included in the pre-clinical and clinical reviews, respectively, where both overall
outcome and wound-healing-phase-specific methodologies and effects were assessed. The pre-clinical
studies demonstrated a promising effect of the application of MSCs on several wound healing
phases. The clinical studies also suggested that the MSC treatment was beneficial, particularly in
the remodeling phase. However, the limited number of studies, their lack of homogeneity in study
design, relatively high risk of bias, lack of reporting on mode of action (MOA), and discontinuity of
evidence restrict the strength of these findings. This comprehensive review presents an overview of
available methodologies to assess the MOA of MSC treatment for distinct wound healing phases.
Furthermore, it includes a set of recommendations for the design of high-quality clinical studies that
can determine the efficacy of MSCs as a therapy for burn wounds.
Keywords: burn wound; mesenchymal stem cell; stem-cell-based treatment; adipose-derived stem
cells; ASC; MSC
1. Introduction
Since the destruction of 15% of the total body skin surface is sufficient to result in a life-threatening
condition, the treatment of severe burn wounds presents a serious medical challenge. Most significantly,
burn wounds are associated with hypovolemic shock, but they can also lead to other dysregulations,
such as hypermetabolism or immunosuppression [1]. Long-term consequences may then involve
scarring, soft-tissue deformities, and fibrosis. These are frequently associated with overall loss of
mobility and pain [2].
The burn wounds are distinctive by a high degree of vascular permeability, but their healing
follows a general paradigm common to all wounds. The reparative processes are initiated with an
inflammatory response, which is histologically marked by neutrophil and macrophage infiltration.
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This phase is followed by a proliferative phase, where new granulation tissue is formed along with new
blood vessels, and the surface is re-epithelialized. During the final phase of maturation/remodeling,
the extracellular matrix (ECM) is remodeled and collagen type III is replaced with collagen type I.
It should be noted that the proliferative phase is impaired with increasing depth of injury, and this has
adverse consequences for the re-epithelialization and remodeling processes. Consequently, the scarring
after severe burns evolves over the years and has a tendency towards hypertrophy [3].
Thus, there is a need for developing approaches that promote healing, reduce scarring, and restore
normal skin function. The application of MSCs has been suggested as a novel therapy for burn
wounds [4], as these cells have been shown to influence a number of factors associated with the
different phases of wound healing. In terms of the effect on the inflammatory phase, MSCs can interact
with cells of the immune system either through secretion of soluble factors or through direct cell–cell
contact. This immunomodulatory interaction with T and B cells, natural killer (NK) cells, neutrophils,
macrophages, and dendritic cells supports a more anti-inflammatory environment [5,6]. The MSCs may
also have an impact on the proliferative phase, as we and others have shown that these cells secrete the
pro-angiogenic vascular endothelial growth factor (VEGF) [7–10], but other factors with pro-trophic
and anti-apoptotic effects appear to play a role as well [11]. The functional significance of the MSC
secretome for wound healing has been demonstrated in vitro in dermal fibroblast-, keratinocyte-,
and endothelial-cell-based scratch assays [12–14]. Finally, regarding the impact on the remodeling
phase, in vitro studies indicate that MSCs produce a number of factors relevant to the composition and
regulation of the ECM [15,16].
The MSCs are found in several tissues, such as the adipose tissue, bone marrow, amniotic
membrane, umbilical cord, and dental pulp. For MSCs derived from adipose tissue (ASCs) and bone
marrow (BM-MSCs), protocols for isolation and expansion of the clinical-grade stem cells have already
been developed, and the clinical utility in at least the selected indications, such as perianal fistulas
or ischemic heart disease, has been confirmed [17–21]. Additionally, clinical studies on diabetic foot
ulcers [22] and venous ulcers [23] are suggestive that MSCs might also be beneficial in the case of burn
wounds; nevertheless, a comprehensive understanding of MSCs’ significance in this scenario is yet to
be obtained.
The aim of this article is to critically access the clinical potential of MSCs for burn wounds. This is
done through two systematic reviews analyzing the current state of knowledge. The first review is
centered on stem cell treatment of burn wounds in rodent models. It attempts to clarify the molecular
and cellular effects of stem cell treatment on the different phases of wound healing. It also strives to
identify methodologies that would be easy to translate into the clinical studies. The second review
deals with clinical studies in order to evaluate the efficacy of MSCs for treatment of severe burn
wounds and to clarify the advancement in the process of clinical translation of the use of stem cells for
burn wounds. The animal-based review is methodologically heavy, but it might be beneficial for the
translation. Furthermore, it might aid the design and increase the quality of future resource-intensive
clinical trials. These are factors that the current literature lacks.
2. Methods
We conducted two systematic reviews—a pre-clinical and a clinical systematic review.
Both systematic reviews were performed according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines [24].
2.1. Search Strategies
An a priori protocol based on the PRISMA-P checklist to perform a systematic literature search was
prepared for both animal and clinical studies and uploaded to the International Prospective Register of
Systematic Reviews (PROPSPERO; protocol ID: CRD42018091050 and CRD42018091793, respectively).
PubMed and Embase were then searched with regards to their individual thesauruses. The following
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primary keyword query was applied: “Burns” AND (“MSC” OR “ASC”). For the complete search
strategies for each database, please refer to Table 1.
Table 1. Database search strategy.
Database Search Strategy
PubMed
(Burn [MeSH] OR “Thermal injury” OR “second degree burn” OR “third degree
burn” OR “skin burn” OR “burn trauma” OR “burn damage” OR “burn wound” OR
“burn injur *”OR “burn patient *” OR “burn lesion” OR “burn complication” OR
“deep burn” OR “thermal burn” OR “deep partial thickness” OR “full thickness”)
AND (Mesenchymal stromal cells [MeSH] OR “Adipose mesenchymal stem cell *”
OR “adipose derived mesenchymal cell *”) AND (“Adipose stromal cell *” OR
“Adipose tissue-derived stem cell *” OR “adipose-derived adult stem cell *” OR
“adipose derived regenerative cell *”)
Embase
(Exp/burn OR Exp/thermal injury) AND (Exp/mesenchymal stem cell OR
Exp/mesenchymal stromal cell OR “Adipose mesenchymal stem cell *”, “adipose
derived mesenchymal cell *”) OR (Exp/adipose derived stem cell OR (“adipose
derived stem cell” OR “adipose stromal cell *” OR adipose tissue-derived stem cell *”
OR “adipose-derived adult stem cell *” OR “adipose derived regenerative cell *”)
* Unlimited truncation.
2.2. Eligibility Criteria
To be valid for inclusion in the review, the studies were required to be either randomized or
non-randomized controlled studies with full-text availability in English published between 2010 and
January 2020. Moreover, the study populations were stipulated to be either rat/mouse dermal burn
models or humans, all with thermal burn or scalding resulting in second- or third-degree burn wounds
of partial or full thickness, or post-burn-wound excisional wounds. The intervention was primarily
stem cell treatment using MSCs derived from the bone marrow, umbilical cord, dental pulp, or adipose
tissue delivered as purified cells or fat grafts.
2.3. Study Selection and Data Extraction
For both reviews, the articles were imported into the Cochrane-partnered software Covidence
(https://www.covidence.org/). Each study was screened by two independent reviewers based on title
and abstract, after which a full-text screening was performed. Studies that did not meet the criteria were
excluded. A bias assessment was performed using the Cochrane risk of bias (RoB) Tool SYRCLE [25]
for the pre-clinical studies or the National Heart, Lung, and Blood Institute (NHLBI) study quality
assessment tools [26] for the human studies. The data extracted from the full papers were population
size and species, intervention type, origin, delivery and dose, comparison, and global outcome.
Additionally, secondary outcome parameters—which included visual appearance, investigations,
or measures of inflammation, proliferation or neovascularization, granulation and re-epithelialization,
and remodeling/scarring—were extracted.
2.4. Assessment of Continuity of Evidence
To assess the continuity of evidence between pre-clinical and clinical studies, as well as among the
clinical studies to justify the clinical translation, a cross-citation analysis was performed. To this end,
the bibliographies of the included clinical studies were examined to identify which of the included
pre-clinical and clinical studies had been cited.
3. Results
The literature searches in Embase and Pubmed resulted initially in 374 and 504 publications,
which, after removal of 73 duplicates, resulted in 805 unique records (Figure 1). These records were
screened for eligibility for inclusion into either the pre-clinical review or the clinical review, first through
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screenings based on title and abstract, then through screening of full texts. The exclusion criteria
were related to the publication, study type, and study setup (for details, please refer to Figure 1).
The exclusion process resulted in a total of 21 pre-clinical and three clinical studies, respectively, which
were included in the subsequent analyses (Figure 1).
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3.1. Bias Assessment
For the pre-clinical studies, the bias assessment revealed that none of the studies reported any
blinding of perso nel or allocation co ceal e t, a o ly 8 o t of the 21 studies reported blinding of
the outcome assessors (Table 2).
Regarding the randomization of the animals, all studies reported random outcome assessment,
15 studies reported random housing, and 12 studies published the method of randomization.
The insufficient documentation as to how both blinding and randomization were performed is
of concern, since these factors are central to accruing valid data.
The bias assessment of the human case studies (Table 3) highlighted the problematic nature of
reporting on only a limited number of patients (one and two, respectively), resulting in a high risk
of bias. The bias assessment of the case–control study Table 3) demonstrated a low risk of bias in
the study.
In future randomized controlled clinical trials investigating the treatment of human burn victims
with stem cells, a detailed description of blinding and randomization as well as the other bias types
should be included. In order to increase the validity and reproducibility of the results, it would be
beneficial if the bias assessment tools were already implemented in the design phase of the clinical
trials. This would, in turn, increase the level of evidence in the produced results.
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Table 2. A visual representation of the risk of bias in animal studies.
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Oryan et al. [27]
Atalay et al. [28]
Eyuboglu et al. [29]
Chen et al. [30]
Loder et al. [31]
Shokrgazor et al. [32]
Kaita et al. [33]
Bliley et al. [34]
Gholipourmalekabadi et al. [35]
Motamed et al. [36]
Abbas et al. [37]
Caliari-Oliveira et al. [38]
Ahmed et al. [39]
Singer et al. [40]
Revilla et al. [41]
Oh et al. [42]
Guo et al. [43]
Xue et al. [44]
Zhang et al. [45]
Pourfath et al. [46]
Gholipour-Kanani et al. [47]
Red: high risk of bias; green: low risk of bias.
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Table 3. A visual representation of the risk of bias in human case series and case-control studies.
(A) A visual representation of the risk of bias in human case series studies.
St
ud
y
Q
ue
st
io
n/
O
bj
ec
ti
ve
St
ud
y
Po
pu
la
ti
on
C
on
se
cu
ti
ve
C
as
es
C
om
pa
ra
bl
e
Su
bj
ec
ts
D
es
cr
ip
ti
on
of
In
te
rv
en
ti
on
O
ut
co
m
e
M
ea
su
re
s
Fo
ll
ow
-U
p
Le
ng
th
St
at
is
ti
ca
lA
na
ly
si
s
W
el
lD
es
cr
ib
ed
R
es
ul
ts
Xu et al., 2012 [48]
Arkilous et al., 2018 [49]
(B) A visual representation of the risk of bias in human case–control studies.
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3.2. Study Characteristics
The 21 pre-clinical studies were published between 2013 and 2019 and the three clinical studies
were published between 2012 and 2018. For both of the systematic reviews, the studies were analyzed
in terms of population, intervention, comparison, global outcome (Tables 4 and 5, respectively), and the
effect of stem cells on the different phases of wound healing (Tables 6 and 7, respectively).
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Table 4. Summary of populations, interventions, comparisons, and global outcomes for pre-clinical studies.
Study
Population Intervention
Comparison Outcome
(Global)Sample
Size Species Type Origin Delivery Dose
Oryan et al., 2019 [27] 12 R ASC Murine Injection 1 × 106
ASC + Aloe Vera
Aloe Vera
Aloe Vera + DBM
DBM
Positive, significantly better
than other groups
Atalay et al., 2014 [28] 20 R ASC * Murine Injection 4 × 106
ASC
Control Positive
Eyuboglu et al., 2018 [29] 20 R ASC * Murine Injection 4 × 106
ASC
Control Positive
Chen et al., 2017 [30] 6 R ASC Murine Injection 1 × 106
ASC
Control Positive
Loder et al., 2015 [31] 20 M ASC Murine Injection 1 × 106
ASC
AT
AT + ASC
Sham
Positive, significantly better
than non-stem cell groups
Shokrgazor et al., 2012 [32] 10 R ASC Murine Graft 5 × 105
ASC
Control Positive
Kaita et al., 2019 [33] 18 M ASC Human Graft 5 × 104
Fresh
Frozen
Control
Positive
Bliley et al., 2016 [34] 24 M ASC Human Injection 6.8 × 106
ASC
Control Positive, but limited
Gholipourmalekabadi et al., 2018 [35] 45 M ASC Human Graft 1 × 104
HAM
HAM + ASC
Control
Positive. More significant in
HAM + ASC
Motamed et al., 2017 [36] 24 R ASC Human Graft 5 × 105
HAM
HAM + ASC
Control
Positive. More significant in
HAM + ASC
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Table 4. Cont.
Study
Population Intervention
Comparison Outcome
(Global)Sample
Size Species Type Origin Delivery Dose
Abbas et al., 2018 [37] 40 R
ASC,
BM-MSC,
DPSC
Human Injection 1 × 106
BM-MSC
ASC
DPSC
Control
Positive, no difference
between choice of stem cells
Caliari-Oliveira et al., 2016 [38] 54 R BM-MSC Murine Injection 5 × 106
MSC
Control Positive
Ahmed et al., 2017 [39] 36 R BM-MSC Murine Injection 1 × 106
MSC
Control
Sham
Positive
Singer et al., 2013 [40] 20 R BM-MSC Murine Injection 1 × 106
MSC
Control Positive
Revilla et al., 2016 [41] 12 R BM-MSC Murine Injection 2 × 106
MSC
Control Positive
Oh et al., 2018 [42] 30 M BM-MSC Murine Injection 5 × 105
MSC
Control
Sham
Positive
Guo et al., 2016 [43] 48 R BM-MSC Murine Graft 5 × 105
SIS
SIS + MSC
Control
Positive. More significant in
SIS + MSC
Xue et al., 2013 [44] 60 M BM-MSC Human Injection 1 × 106
MSC
Control Positive
Zhang et al., 2015 [45] 84 R UC-MSC Human Injection 2 × 106
MSC
Control Positive
Pourfath et al., 2018 [46] 24 R UC-MSC Human Spray 5 × 105
MSC
Control Positive
Gholipour-Kanani et al., 2014 [47] 12 R UC-MSC Human Graft 4 × 104
MSC
Control Positive
ASC: adipose-derived stem cells, AT: adipose tissue, BM-MSC: bone-marrow-derived mesenchymal stem cells, DBM: demineralized bone matrix, DPSC: dental pulp stem cells, HAM:
human amniotic membrane, M: mouse, MSC: mesenchymal stem cells, R: rat, SIS: small intestine submucosa, UC-MSC: umbilical cord mesenchymal stem cells. * ASCs delivered as
stromal vascular fraction.
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Table 5. Summary of populations, interventions, comparisons, and global outcomes for clinical studies.
Study
Population Intervention
Comparison
Outcome
Sample
Size Species Type Origin Delivery Dose (Global)
Xu et al., 2012 [48] 1 H BM-MSC Autologous Injection 2.1 × 106/mL
BM-MSC +
Decellularized
allogeneic dermal
matrix + Skin graft
Decellularized
allogeneic dermal
matrix + Skin graft
Positive -
Arkoulis et al.,
2018 [49] 2 H ASC * Autologous Topical 46,400/cm
2 Pre-intervention Post-intervention Positive -
Abo-Elkheir et al.,
2017 [50] 60 H
BM-MSC Autologous Injection 1 × 105/mL/cm2 × 2
BM-MSC + dressing
with gentamicin
UC-MSC + dressing
with gentamicin Standard
treatment
Positive
UC-MSC Allogeneic ointment ointment
ASC: adipose-derived stem cells, BM-MSC: bone-marrow-derived mesenchymal stem cells, H: human, UC-MSC: umbilical cord mesenchymal stem cells. * ASCs delivered as stromal
vascular fraction.
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Table 6. Analysis of the outcomes according to the phases of wound healing in pre-clinical trials.
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Oryan et al., 2019 [27]
Atalay et al., 2014 [28]
Eyuboglu et al., 2018 [29]
Chen et al., 2017 [30]
Loder et al., 2015 [31]
Shokrgazor et al., 2012 [32]
Kaita et al., 2019 [33]
Bliley et al., 2016 [34]
Gholipourmalekabadi et al., 2018 [35]
Motamed et al., 2017 [36]
Abbas et al., 2018 [37]
Caliari-Oliveira et al., 2016 [38]
Ahmed et al., 2017 [39]
Singer et al., 2013 [40]
Revilla et al., 2016 [41]
Oh et al., 2018 [42]
Guo et al., 2016 [43]
Xue et al., 2013 [44]
Zhang et al., 2015 [45]
Pourfath et al., 2018 [46]
Gholipour-Kanani et al., 2014 [47]
Green: Positive effect; red: non-significant difference or contradictory results; yellow: no difference; grey:
not assessed.
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Table 7. Analysis of the outcomes according to the phases of wound healing in clinical trials.
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Green: Positive effect; red: non-significant difference or contradictory results; grey: not assessed.
3.2.1. Population
The pre-clinical studies were all in vivo studies and the population size varied between 6 and
84 animals, with an average of 29.5 animals per study. The majority (15) of the studies were based on a
rat model, and a mouse model was employed in six instances. The clinical studies consisted of one
case–control study with 60 patients in total and two case reports with one or two patients.
3.2.2. Intervention
For the analysis of the intervention used across studies, information about the type and origin of
stem cells, delivery method, and dose was extracted.
Of the 21 pre-clinical studies, 10 used ASCs, which, in two cases, were in the form of stromal
vascular fraction (SVF), seven studies used BM-MSCs, one study used ASCs, BM-MSCs, and dental
pulp stem cells (DPSCs), and three studies used umbilical cord (UC)-MSCs. Stem cells from the same
species were used in 12 studies, and human stem cells were used in nine. The method of delivery
varied, with 14 studies using injection, six using graft, and one using spray. The doses used covered a
broad range from 1 × 104 to 6.8 × 106 cells, with an average of 1.6 × 106 cells.
For the clinical studies, one used ASCs in the form of SVF. The two other studies used BM-MSCs,
and one additionally used UC-MSCs. All BM-MSCs were autologous, and the UC-MSCs were
allogeneic. The method of delivery was either injection or topical administration. The doses used
in the three different studies are incomparable, as they are stated in either cells/mL/cm2, cells/mL or
cells/cm2. It is also notable that the treatment in the case–control study by Abo-Elkheir et al., 2017 [50]
was repeated twice.
3.2.3. Comparison
All the pre-clinical studies included a control group, a sham group (1 study), or both (2 studies).
In four studies, the stem cells were used in combination with either aloe vera, human amniotic
membrane (HAM), or small intestine submucosa (SIS), whereas in the remaining 17 studies, only the
stem cells were administered.
The three clinical studies compared the effect of stem cell treatment either to a control group
using the standard treatment of early excision and grafting, to a wound not receiving stem cells
on the opposite arm of the included patient, or to the pre-intervention wound state. One study
investigated the effect of stem cells together with a dressing with gentamicin ointment, one together
with a decellularized allogeneic dermal matrix and a skin graft, and the last one together with an
Integra template.
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3.2.4. Outcome
Overall, in all pre-clinical studies, the application of mesenchymal stem cells to the in vivo burn
wound models had a positive effect (Table 4). A more detailed analysis of the effect of stem cells on the
different phases of wound healing is presented in Table 6.
Of the 17 studies that assessed wound healing by either measuring the wound area or closure rate,
15 found a positive effect, one study did not show a significant effect, and one study documented no
effect. The effect of stem cells on inflammation was evaluated in 12 studies. Of those, 10 demonstrated
an anti-inflammatory effect and two studies were inconclusive. Of the 13 studies that evaluated the effect
on neovascularization, 12 showed a positive effect and one was inconclusive. Regarding granulation,
13 studies demonstrated a positive effect and one study showed no effect. As for re-epithelialization,
11 studies demonstrated a positive effect and one study showed no effect. The effect of stem cells on
remodeling and scarring was investigated in eight studies; five of these demonstrated a positive effect,
two were inconclusive, and one reported no difference.
All three clinical studies found a positive effect of the application of mesenchymal stem cells to the
burn wounds. However, in the case–control study by Abo-Elkheir et al. (2017), infection was observed
in 25–70% of patients receiving stem cell treatment compared to 25% in the control group (Table 7).
Xu et al. (2012) found no difference in the overall healing, as both wounds in the trial subject
were healed when progress was investigated. Moreover, no difference in inflammation was observed,
as none of the wounds became infected. All three studies found a positive effect on scarring with a
noticeable decrease in contracture.
3.3. Outcome Assessment Parameters
For each of the studies, the phases of the wound healing were further characterized by invoking
additional outcome assessment parameters (Tables 8 and 9). For the animal studies, a range of both
non-invasive and invasive methods were applied. However, in the case of clinical studies, only visual
assessment was used for the evaluation of overall wound healing and for the evaluation of the effect of
stem cells on the different phases (Table 9).
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Table 8. Outcome assessment parameters from pre-clinical trials.
Study Wound Healing Inflammation
Proliferation
Remodeling/Scarring
Neovascularization Granulation Re-Epithelialization
Oryan et al., 2019 [27] Wound area, Rate of woundclosure (NI)
Inflammation markers (visual
inspection, NI). Inflammatory
cell infiltration (H, BI). IL-1b,
TGF-β1, bFGF (qPCR, BI)
Capillary density (H, BI)
Collagen structure (SEM, BI).
Number of fibroblasts and
fibrocytes (H, BI). Collagen
level (Hydroxyproline, BI)
Epidermal formation (H, BI) Connective tissuearrangement (H, BI)
Atalay et al., 2014 [28]
Polymorphonuclear and
mononuclear inflammatory
infiltrate score (H, BI)
VEGF index (VEGF; H + I, BI) Cell proliferation index(PCNA; H + I, BI)
Eyuboglu et al., 2018 [29] Area of necrosis (NI) Neutrophil score (H, BI)
Capillary count
(Angiography + H, BI).
Vascular density grading
(H, BI). Endothelial count
(vWF; H + I, BI)
Epithelial thickness (H, BI) Fibrosis gradient(Masson’s trichrome, BI)
Chen et al., 2017 [30] Wound area, Rate of woundclosure (NI)
Lymphocytic inflammatory
infiltration (H, BI) Epithelial regeneration (H, BI)
Pathologic dermal
fibrosis (H, BI)
Loder et al., 2015 [31]
Wound area closure (NI).
Wound depth,
Rate of wound closure (BI)
Endothelial count
(CD-31; H + I, BI) Proliferation (Ki67; H + I, BI)
Shokrgazor et al., 2012 [32] Wound area (NI) Epidermal formation (H, BI)
Kaita et al., 2019 [33] Wound area, Rate of woundclosure (NI) Neovascularization (IB4; I, BI)
Collagen production
(Picro-Sirus Red,
Col I/III; H + WB + qPCR, BI)
Skin thickness ratio (Masson’s
trichrome, BI)
Bliley et al., 2016 [34]
Wound area, Rate of
wound closure,
Wound area, Time to
healing (NI)
Vascularity (CD31; H + I, BI)
Collagen production
(Picro-Sirius Red, Masson’s
trichrome; H) (Col I, Col III;
qPCR, BI)
Wound contraction (α-SMA;
qPCR, BI)
Collagen production (Col I and
III; qPCR, BI)
Gholipourmalekabadi et al., 2018 [35]
Wound area, Rate of wound
closure, Wound area (NI).
Wound-healing scoring (H, BI)
Acute inflammatory cells
(H, BI). Localized
Inflammatory Response (MIP2,
TNFα1, and TGFβ1; qPCR, BI)
Capillary density (CD31; I, BI).
Neovascularization score
(CD31, VEGF- α1, VEGFR2; I,
BI). Neovascularization rate
(IL-1b, bFGF, VEGF-α1,
VEGFR2; qPCR, BI)
Deposition of the extracellular
matrix (H, BI). Collagen
deposition score (Masson’s
trichrome, BI). Density of Col I,
III, and IV (I, BI).
Hair follicle formation (H, BI).
Re-epithelialization (H, BI),
Epidermal Thickness Index.
Maturation (Masson’s
trichrome, BI). Scar formation
(Col I, III, and IV; I) (Col I, III,
IV, MIP-2, TGFβ1, TNFα1,
MMP-1, MMP-2; qPCR, BI).
Scar Elevation Index.
Motamed et al., 2017 [36] Wound area, Rate of woundclosure (NI)
Acute inflammatory cells
(polymorphonuclear cells,
eosinophils; H + Masson’s
trichrome, BI), Chronic
inflammatory cells (histocytes,
lymphocytes, plasma cells;
H + Masson’s trichrome, BI)
Epidermal and dermal
structures, re-epithelialization,
epithelium thickness,
rete-ridges, dermal
appendages (H + Masson’s
trichrome, BI)
Pathologic dermal fibrosis
(H + Masson’s trichrome, BI)
Abbas et al., 2018 [37] Area of necrosis (NI) Inflammatory Cell Infiltration(myeloperoxidase activity, BI)
Microvascular density
(CD31; H + I, BI)
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Table 8. Cont.
Study Wound Healing Inflammation
Proliferation
Remodeling/Scarring
Neovascularization Granulation Re-Epithelialization
Caliari-Oliveira et al., 2016 [38] Wound areaRate of wound closure (NI)
Bacterial contamination
(swabs, NI).
Total polymorphonuclear
inflammatory cells score (H, BI).
Neutrophils accumulation
(myeloperoxidase assay, BI).
CD4+ T-cells and CD8+ T-cells
(Flow, BI). IL-10, IL-6, TGF-β,
CINC-1 (ELISA, BS)
Vascularization score (H, BI) Granulation tissue thicknessscore (H, BI) Collagen fiber score (H, BI)
Ahmed et al., 2017 [39]
Acute inflammatory cells
(H, BI). IL-10, TNF-α, TGF-β
(ELISA, BS)
Capillaries (H, BI), TGF-β
(ELISA, BS). PDGF (I, BI).
ANG-1, ANG-2 (qPCR, BI)
TGF-β (ELISA, BS). PDGF
(I, BI). Vimentin (qPCR, BI)
Epithelialization (H, BS),
TGF-β (ELISA, BS). MMP-1,
TIMP-2 (qPCR, BI)
TGF-β (ELISA, BS)
Singer et al., 2013 [40] Area of necrosis (NI)
Revilla et al., 2016 [41] Wound appearance (NI) Collagen type I fiber thickness,Integrin a2b1 (H + I, BI)
Oh et al., 2018 [42] Inflammatory cell infiltration(Masson’s trichrome, BI)
Collagen production (Masson’s
trichrome, BI).
TGF-β1 and VEGF (WB, BI)
Guo et al., 2016 [43]
Wound area,
Rate of wound healing (NI).
Wound maturity score (H, BI)
Capillary density (vWF; I, BI) Granulation score (Collagen;Masson’s trichrome, BI)
Neoepithelium length (H, BI).
Epidermal cell
proliferation (Ki-67; I, BI)
Xue et al., 2013 [44] Wound area, Rate of woundhealing (NI)
Capillary density (H, BI). VEGF,
Ang-1/2, CD31 (qPCR, WB, BI).
Zhang et al., 2015 [45] Wound healing rate andtime (NI)
WBC (count, BS). CRP
(nephelometric immunoassay
method, BS). IFN-γ, TNF-α,
IL-6, IL-10 (ELISA, BS)
Capillary density (H, BI)
Granulation tissue amount
(H, BI). Number of
fibroblasts (H, BI)
Pourfath et al., 2018 [46] Granulation (H, BI) Re-epithelialization (H, BI)
Gholipour-Kanani et al., 2014 [47] Wound area (NI). Total woundhealing score (H, BI)
Inflammation markers (visual
inspection, NI). Inflammatory
cell infiltration (H, BI)
Collagen regeneration and
granulation tissue
thickness (H, BI)
Epithelial regeneration,
appendage (H, BI)
ANG-1/2: Angiopoietin-1/2, α-SMA: alpha smooth muscle actin, bFGF: basis fibroblast growth factor, BI: biopsy, BS: blood sample, CD-31: platelet endothelial cell adhesion molecule,
CINC-1; cytokine-induced neutrophil chemoattractant, Col: collagen, CRP: C-reactive protein, ECM: extracellular matrix, ELISA: enzyme-linked immunosorbent assay, H: histology, I:
immunohistochemistry, IFN-γ: interferon gamma, IL: interleukin, IB4: isolectin B4, Flow: flowcytometry, MIP-2: macrophage-inflammatory protein 2, MMP: matrix metalloproteinase, NI:
non-invasive, PCNA: proliferating cell nuclear antigen, PDGF: platelet-derived growth factor, qPCR: quantitative polymerase chain reaction, SEM: scanning electron microscopy, TGF-β:
transforming growth factor beta, TIMP-2: tissue inhibitor of metalloproteinases 2, TNFα: tumor necrosis factor alpha, VEGF: vascular endothelial growth factor, VEGFR2: vascular
endothelial growth factor receptor 2, vWF: von Willebrand factor, WB: western blot, WBC: white blood count.
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Table 9. Outcome assessment parameters from clinical trials.
Study Wound Healing Inflammation Proliferation Remodeling/Scarring
Xu et al., 2012 [48] Overall healing (visual) Infection (visual) Contracture (visual)
Arkoulis et al., 2018 [49] Contracture (visual)
Abo-Elkheir et al., 2017 [50]
Type of burn
Onset, cause, mechanism, site, wound
percentage (Lund and Browder), area of
wound, depth of wound, rate of healing
Infection (visual)
Hypertrophic scars,
keloid, contracture,
and pigmentation (visual)
3.3.1. Wound Healing
Non-invasive assessment of overall wound healing was used in 17 of 21 studies in the form of
either end-point measurements or rate of wound closure. Some studies determined the necrotic area as
a measure of tissue damage. In addition to the non-invasive assessment, four studies applied a wound
healing or maturation scoring system based on histological data.
3.3.2. Inflammation
Non-invasive assessment of inflammation or infection was used in three studies. The assessments
included signs of inflammation, such as redness, heat, and swelling, and the bacterial contamination
was determined by swabbing. Biopsies were used for histological assessment of the infiltration by
inflammatory cells (11 studies), and quantitation of expression of interleukin-1b (IL-1b), transforming
growth factor beta 1 (TGF-β1), basic fibroblast growth factor (bFGF), macrophage-inflammatory protein
2 (MIP2), or tumor necrosis factor-alpha 1 (TNFα1) was assessed using quantitative polymerase chain
reaction (qPCR) (two studies), myeloperoxidase activity (two studies), and flow cytometry of the
CD4+ and CD8+ T cells (one study). Three studies used blood samples to determine white blood
cell count or c-reactive protein (CRP) levels, or used enzyme-linked immunosorbent assay (ELISA) to
quantitate levels of IL-6, IL-10, TGF-β, cytokine-induced neutrophil chemoattractant (CINC-1), TNF-α,
and interferon gamma (IFN-γ).
3.3.3. Proliferation
Our data analysis of the methods used to analyze the proliferative phase of wound healing divides
them further into three processes—neovascularization, granulation, and re-epithelialization.
Neovascularization
Most of the studies investigated neovascularization based on biopsies. The methods included
histomorphometry to determine capillary density (six studies), immunohistochemistry to investigate
the presence of platelet-derived growth factor (PDGF), VEGF, vascular endothelial growth factor
receptor 2 (VEGFR2), or isolectin B4 (IB4) as a measure of neovascularization, as well as the presence
of von Willebrand factor (vWF) or platelet endothelial cell adhesion molecule (CD31) to estimate the
number of endothelial cells (nine studies). Furthermore, qPCR was used to study the expression of
IL-1b, bFGF, VEGF-α1, VEGFR2, angiopoietin 1 and 2 (Ang-1/2), or CD31 (three studies), one study
used western blotting (WB) to determine the levels of VEGF, Ang-1/2, and CD31, and, finally, in one
study, blood samples were tested for TGF- β using ELISA.
Granulation
The process of granulation was, in most studies, evaluated in biopsy samples. Histological
analysis was used to determine the degree of cell proliferation (three studies) and the presence of
fibroblasts and/or fibrocytes (two studies), as well as to characterize the ECM in terms of the amount
and composition of collagens (seven studies) and integrins (one study). In one study, the ECM was
analyzed by scanning electron microscopy. The transcriptional activation of collagen I, collagen III,
or vimentin genes was determined by qPCR in three studies. WB was used to assess the amount of
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collagen I, collagen III, TGF-β, or VEGF in two studies, and, lastly, a serum-based ELISA was used in
one study to measure the level of TGF-β.
Re-Epithelialization
In all 12 studies that specifically dealt with the process of re-epithelialization, the evaluation
was done using biopsies. Eleven studies used histological analysis to determine the epidermal
formation, epidermal cell proliferation, epidermal thickness, hair follicle formation, rete-ridges,
and dermal appendages. qPCR was used in two studies to either investigate wound contraction by
alpha smooth muscle actin (α-SMA) or to investigate metalloproteinases and their inhibitors: matrix
metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinases 2 (TIMP-2). One study used a
serum-based ELISA to measure the level of TGF-β.
3.3.4. Remodeling/Scarring
Of the 21 studies, only seven investigated the processes of remodeling and scarring. Of these,
six were based on biopsies and included histological assessment of connective tissue arrangement or
pathologic dermal fibrosis. Immunohistochemistry was used in one study to quantitatively evaluate
scar formation by means of visualization of collagens I, III, and IV. Additionally, qPCR was used in
two studies to determine the transcriptional levels of collagens I, II, and IV, MIP-2, TGF-β1, TNF-α1,
and MMP-1 and -2. Furthermore, in one study, ELISA was used to assay the serum level of TGF-β.
3.4. Pre-Clinical to Clinical Continuity of Evidence
When performing a cross-citation analysis to assess the evidence used to justify clinical translation,
none of the pre-clinical studies were identified in the bibliographies of any of the clinical studies.
Moreover, none of the clinical studies cited the other clinical studies.
4. Discussion
In the current systematic review, we have evaluated the research of therapeutic use of stem cells
towards healing of burn wounds. A total of 21 pre-clinical and three clinical studies were included.
The pre-clinical studies investigated wound healing by looking at different micro-processes of the
different wound healing phases, such as inflammation, proliferation, neovascularization, granulation,
re-epithelialization, and remodeling/scarring. Noticeably, the studies varied widely due to differences
in scientific focus, research strategy, and methods used; therefore, it was not possible to directly
compare their findings. Nevertheless, there was apparent positive effect of MSCs on the overall
healing, and the majority of studies agreed on the positive effect on all of the individual phases as
well (Table 5). From the temporal viewpoint, most of the studies investigated the progressive effect of
MSCs, typically 7, 14, and 21/28 days after burn infliction; however, some studies also looked at the
effect after 40–60 days. The effect was most evident between 7 and 21 days, at which point 90% of the
wounds were healed. It should be noted that a rapid wound closure is of importance to decrease the
risk of hypermetabolism, infection, and hypovolemic shock [1].
In order to identify the wound healing processes where the MSCs exerted their regenerative
properties, the effect on each phase and the related specific micro-processes were examined. For the
inflammation phase, 10 out of 12 studies reported immunomodulatory effects. For neovascularization,
12 out of 14 studies found a positive effect. Effects were also found in 13 out of 14 studies in regard to
the granulation phase, as well as 11 out of 12 studies for the re-epithelialization phase. Only eight
studies examined the effect of treatment on the remodeling/scarring phase. Out of these, five reported a
positive effect, which was, incidentally, associated with the use of ASCs. That ASCs may be specifically
useful in this stage, where extensive ECM remodeling takes place, also gains support from an in vitro
line of evidence [15]. In burn wounds, the importance of this phase cannot be overstated, as scarring,
soft tissue deformities, and fibrosis represent serious long-term consequences [2].
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To evaluate the mechanism of action of MSCs in the healing of burn wounds, a frequently
used approach was the histological assessment. However, due to the non-quantitative nature of this
procedure, it was difficult to arrive at evidence-based conclusions. Some of the studies converted their
findings into semi-quantitative scoring systems to enable a sort of comparison. In the face of obvious
deficiency of such attempts, it would be of great value if a unified scoring system was developed
and adopted across the wound healing research community. It is important that future studies strive
to incorporate quantitative assays in their experimental design as much as possible, and that these
approaches are applied in a way reflecting wound pathogenesis. As an example, we have identified
several studies that attempted to determine the role of bFGF or TGF-β. Despite providing information
about overall production, they were not able to highlight an association of these factors with a particular
phase of healing. This could have been useful, since such information would facilitate a more in-depth
understanding of the MSCs’ interaction with the wound microenvironment. Future animal studies
should also apply tools like SYRCLE in the design stage. This, including the minimization of risk of
bias, should clearly be spelled out in the published works. Moreover, new studies should be designed
to be confirmatory studies, as these are increasingly considered to be the necessary prerequisite for
clinical trials [51,52].
Although a substantial number of studies involving MSC application have been conducted in
animal models, very few studies have been investigating the effect in humans. These studies have
yielded a very low level of evidence due to the study type and very limited outcome measures.
To take MSCs into consideration as a standard treatment option, the amount of evidence needs to be
considerably increased. To this end, randomized controlled trials need to be designed with emphasis
on risk of bias, sample size, and choice of primary and secondary outcome measures. Additionally,
it is important that the knowledge gap is addressed, and the available clinical and pre-clinical evidence
is used in the rationalization step. When undertaking these studies, it is encouraged to thoroughly
consider the risk areas, such as the randomization process, deviations from intended interventions,
missing outcome data, measurement of the outcome, or selection of the reported results, which
can all lead to high risk of bias in randomized controlled trials. These areas can be found through
risk assessment tools, such as the Cochrane risk of bias tool (RoB2) [53]. Another important factor,
that should be given thorough consideration, is the sample size, since this variable is critical for the
outcome of statistical analysis in terms of significance and power. However, as a large study population
can be difficult to muster, due to the incidence of burn wounds, it should be remembered that sample
size and covariates must be balanced, especially in smaller clinical trials [54,55].
It appears that the most meaningful progress in understanding the clinical utility of MSCs
would occur if the primary and secondary outcome measures included quantitative analysis of the
biopsy samples for investigating specific markers for each of the wound healing phases. Histological
analysis of the biopsies could include quantitation of infiltrating inflammatory cells, proliferating
endothelial cells or fibroblasts, or collagen composition to assess progression through the inflammation,
proliferation, or remodeling phases, respectively. However, ethical concerns regarding inflicting further
trauma make it difficult to collect biopsies from these complex wounds. In case the justification is
serious enough to warrant the sampling, it must be guaranteed that the utilization of the material is
maximized. Therefore, a well-designed panel of quantitative assays should be conducted to clarify
MOA. In cases where more than one biopsy during the healing period is needed, the timing of these
should be designed to specifically target the different wound healing phases. Based on the animal
studies reviewed in this paper, we suggest days 7, 14, and 21, and perhaps a biopsy after a year to
monitor the long-term wound maturation.
The presented evidence indicates that the stem cell treatment is generally beneficial, although it
seems that the animal model is not entirely identical to the human scenario. Notably, we observed
that whereas the MSCs appeared effective throughout all phases of wound healing in the pre-clinical
trials, their effect was mostly reduced to modulation of scarring and contracture in patients. Moreover,
we noted an obvious lack of coherence in knowledge translation from bench to bedside, and the
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number of clinical studies was disappointingly low and had a very low evidence level with a high
risk of bias. Thus, more clinical studies are needed, and, hopefully, identifying and recognizing the
knowledge gaps and the discontinuity from pre-clinical to clinical research may promote better design
of future clinical studies.
In summation, this article, based on two systematic reviews, provides a comprehensive overview
of the available methodologies and MOA of MSC treatment of burn wounds from both pre-clinical
and clinical studies. Although the animal trials produced some exciting results, it is evident that
high-quality randomized controlled trials are required before drawing universal conclusions about the
clinical effect of stem cell treatment in burn wounds.
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